Background: Little is known about the diagnosis and management of restless legs syndrome (RLS) in Japanese neurology clinics.
Objective: To validate the diagnostic criteria of the International RLS Study Group (IRLSSG) and the treatment algorithm of the Mayo Clinic in a Japanese neurology clinic setting and to clarify the features of Japanese patients with idiopathic RLS.
Methods: Patients with RLS symptoms were examined by a neurologist and the assessment included neurological examination, tests for periodic limb movements (PLM) and dopaminergic response, and the clinical diagnosis was made according to IRLSSG diagnostic criteria. Patients diagnosed with idiopathic RLS were treated with dopaminergic agents and the efficacy was evaluated.
Results: The study subjects were 151 Japanese patients who presented with RLS symptoms. Idiopathic RLS was diagnosed in 113 patients, secondary RLS in 16 and RLS mimics in 22. The cause of RLS mimics was either myelopathy, radiculopathy or neuropathy in 11 patients. The mean age of patients with idiopathic RLS was 50.1 (SD 20.0) years, 63% were woman, 97% had daily RLS, 31% had family history (40% of the early-onset subgroup), 86% reported unpleasant sensations in the lower legs, 43% had PLM in the daytime suggested immobilization test, 81% suffered from insomnia, 49% had limitations of work and activities, 71% reported impaired mood, 27% had consulted physicians about their symptoms, 4% had been diagnosed with RLS, 73% improved after dopaminergic treatments, and 33% experienced complete remission.
Conclusions: The clinical features of Japanese patients with idiopathic RLS were identical to those reported in western countries, which suggests that IRLSSG diagnostic criteria and Mayo Clinic treatment algorism are valid in Japanese neurology clinics. Both patients and physicians were not fully aware of RLS in this country. Neurological examination was important in excluding RLS mimics and making a diagnosis of RLS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5692/clinicalneurol.50.385 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of continuous positive airway pressure therapy on restless legs syndrome in patients with coexistent obstructive sleep apnea: A qualitative systematic review.
J Clin Neurosci
January 2025
Department of Neurology, Yale University, New Haven, CT, USA.
Introduction: Obstructive sleep apnea (OSA) is characterized by repetitive episodes of complete or partial upper airway collapse during sleep. Restless legs syndrome (RLS) is a sleep-related movement disorder characterized by an uncomfortable urge to move the legs, especially during inactivity and evenings. Both OSA and RLS are common with significant overlap: RLS is present in up to 36% of those with OSA.
View Article and Find Full Text PDFTransdermal electrophysiological recordings of diet-induced small fiber peripheral neuropathy using a needle electrode array in mice and man.
Front Bioeng Biotechnol
January 2025
Department of Neurological Surgery, The Ohio State University, Columbus, OH, United States.
Background: Diabetic peripheral neuropathy (DPN) is a common complication of diabetes. Proactive treatment options remain limited, which is exacerbated by a lack of sensitive and convenient diagnostics, especially early in disease progression or specifically to assess small fiber neuropathy (SFN), the loss of distal small diameter axons that innervate tissues and organs.
Methods: We designed, fabricated, tested, and validated a first-of-its-kind medical diagnostic device for the functional assessment of transdermal small fiber nerve activity.
Circadian pattern in restless legs syndrome.
Handb Clin Neurol
January 2025
Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.
This chapter provides an overview of circadian pattern in restless legs syndrome (RLS). Circadian variation of symptoms is a known feature of RLS. According to one of the five essential criteria for RLS diagnosis, symptoms "only occur or are worse in the evening or at night than during the day.
View Article and Find Full Text PDFEstablishment of iPSC-Derived MSCs Expressing hsa-miR-4662a-5p for Enhanced Immune Modulation in Graft-Versus-Host Disease (GVHD).
Int J Mol Sci
January 2025
Catholic High-Performance Cell Therapy Center & Department of Medical Life Science, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul 06591, Republic of Korea.
The immune-modulatory effects of mesenchymal stromal cells (MSCs) are widely used to treat inflammatory disorders, with indoleamine 2,4-dioxygenase-1 (IDO-1) playing a pivotal role in suppressing stimulated T-cell proliferation. Taking that three-dimensional (3D) cultures enhance MSCs' anti-inflammatory properties compared with two-dimensional (2D) cultures, the differentially expressed miRNAs were examined. Thus, we identified hsa-miR-4662a-5p (miR-4662a) as a key inducer of IDO-1 via its suppression of bridging integrator-1 (BIN-1), a negative regulator of the IDO-1 gene.
View Article and Find Full Text PDFSilver-Treated Sutures for the Prevention of Biofilm-Associated Surgical Site Infections.
Antibiotics (Basel)
January 2025
Department of Experimental Medicine, University of Salento, Via Monteroni, 73100 Lecce, Italy.
Background/objectives: The huge concerns associated with biofilm-related infections in surgical procedures, along with the antibiotic resistance demonstrated by an increasing number of bacteria, have highlighted the need for alternative and effective prevention approaches. The aim of this research was to develop novel antimicrobial coatings on surgical sutures for the prevention of surgical site infections through nanotechnology-based methods.
Results: The results demonstrated that although very low amounts of silver precursor were adopted for the treatments, the silver coating was effective against and antibiotic-resistant in reducing the potential risk of infection.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!